BRAF and cancer: In the combined sample, BRAF mutation status and ECOG-PS (ECOG-PS=0 vs ECOG-PS≥1) were not associated with either ORR or OS (p>0.05), while higher cancer stage was associated with both poorer ORR (OR[95% CI]=0.62[0.39–0.94]; p=0.030) and OS (HR[95% CI]=1.52 [1.05–2.19]; p=0.026), after accounting for age, sex and BMI.